INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

Estimated average burden
OMB Number:			3235-0104
hours per response:			0.5

1. Name and Address of Reporting Person^*

Williams Mitchell Young

(Last)

(First)

(Middle)

C/O BIOSIG TECHNOLOGIES, INC.

12424 WILSHIRE BLVD., STE. 745

(Street)

LOS ANGELES

90025

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
05/28/2025

3. Issuer Name and Ticker or Trading Symbol
BioSig Technologies, Inc. [ BSGM ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Chief Investment Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Restricted Common Stock	1,000,000⁽¹⁾	D

**Table II - Derivative Securities Beneficially Owned**
**(e.g., puts, calls, warrants, options, convertible securities)**
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Exchangeable Shares⁽²⁾	⁽²⁾	⁽²⁾	Common Stock	937,382⁽²⁾	⁽²⁾	D

Explanation of Responses:

1. Represents a restricted stock award of 1,000,000 shares of common stock, par value $0.001 per share (the "Common Stock") of BioSig Technologies, Inc. (the "Company") granted pursuant to the Company's 2023 Equity Incentive Plan. One-third of the shares (333,334 shares) will vest on the three-month anniversary of the grant date, subject to the reporting person's continued service with the Company through such date. The remaining two-thirds of the shares will vest in five subsequent quarterly installments-four equal installments of 133,333 shares each on each quarterly anniversary of the initial vesting date, and a final installment of 133,334 shares on the eighteen-month anniversary of the grant date-subject to continued service through each applicable vesting date.

2. Represents the Common Stock that may be issued from time to time upon the exchange, retraction or redemption of exchangeable shares of BST Sub ULC, an unlimited liability company organized under the laws of the Province of British Columbia and a wholly-owned subsidiary of the Company (the "Exchangeable Shares"). Each Exchangeable Share may be exchanged for one share of Common Stock, subject to certain exceptions. The aggregate number of Exchangeable Shares that may be exchanged for Common Stock may not exceed 19.9% of the total outstanding Common Stock until such issuance is approved by the Company's stockholders. The Exchangeable Shares do not have an expiration date.

	/s/ Mitchell Young Williams	06/09/2025
	** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.